BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tenofovir alafenamide (Vemlidy) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tenofovir alafenamide (Vemlidy)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06221657-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT06221657)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: Clinical Trial for Non-inferiority and Safety of Tenofovir Alafe
 namide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Mali
 gnancies Who Require Prophylactic Hepatitis B Antiviral Treatment\nEstimat
 ed primary completion: 1 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06221657
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946757-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 1 readout est. (NCT07946757)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 1\, Chronic Hepatitis B
 .\nStudy: Phase Ib Clinical Trial of ACT201 Injection in Participants With
  Treatment-Naïve Chronic Hepatitis B\nEstimated primary completion: Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-a
 lafenamide-vemlidy#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07946757
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668934-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT07668934)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: TAF in Early/Middle Pregnancy With CHB\nEstimated primary comple
 tion: 30 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tenofovir-alafenamide-vemlidy#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07668934
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203118-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 2/3 readout est. (NCT0720311
 8)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 2/3\, Chronic Hepatitis
  B.\nStudy: A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chron
 ic Hepatitis B\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07203118
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253220-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:tenofovir alafenamide (Vemlidy): Phase na readout est. (NCT07253220
 )
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase na\, Chronic Hepatitis 
 B.\nStudy: TAF Monotherapy Versus ETV Combined With TAF on the Efficacy an
 d Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcin
 oma\nEstimated primary completion: 30 September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07253220
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03933384-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT03933384)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: Tenofovir Alafenamide Versus Entecavir for the Treatment of Chro
 nic Hepatitis B\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0393
 3384
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04939441-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT04939441)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04939441
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05195450-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase na readout est. (NCT05195450
 )
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase na\, Chronic Hepatitis 
 B.\nStudy: TAF (Tenofovir Alafenamide) for Preventing Progression of Liver
  Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Vi
 ral Load.\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05195450
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05652478-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 2 readout est. (NCT05652478)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 2.\nStudy: Early Metabo
 lic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Rando
 mized Study\nEstimated primary completion: 31 January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05652478
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947356-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:tenofovir alafenamide (Vemlidy): Phase na readout est. (NCT06947356
 )
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase na\, Chronic Hepatitis 
 B.\nStudy: Comparison of TAF and TDF in Preventing Mother-to-Child Transmi
 ssion of HBV in Pregnancies With High Viral Loads\nEstimated primary compl
 etion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 nofovir-alafenamide-vemlidy#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06947356
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 3 readout est. (NCT07797231)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 3\, Chronic Hepatitis B
 .\nStudy: Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)I
 de Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chro
 nic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit L
 ow Viral Load or Poor Response\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafena
 mide-vemlidy#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07797231
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542951-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT07542951)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: TAF vs TDF During the Pregancy\nEstimated primary completion: 1 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofo
 vir-alafenamide-vemlidy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07542951
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258251-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT07258251)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: Strengthening Hepatitis B Screening\, Linkage to Care and Long-T
 erm Monitoring in Phichit Province\, Thailand: A Birth Bohort Approach\nEs
 timated primary completion: 31 December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07258251
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06707922-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:tenofovir alafenamide (Vemlidy): Phase na readout est. (NCT06707922
 )
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase na\, Chronic Hepatitis 
 B.\nStudy: A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in
  Patients With Chronic Hepatitis B\nEstimated primary completion: 31 May 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafen
 amide-vemlidy#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06707922
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 3 readout est. (NCT07792096)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 3.\nStudy: An Adaptive 
 Platform Trial for Evaluation of Novel Treatment Regimens in Children and 
 Adolescents With HIV in Africa\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-
 vemlidy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07792096
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03753074-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 4 readout est. (NCT03753074)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 4\, Chronic Hepatitis B
 .\nStudy: Effectiveness of TAF in Reducing Clinical Events in CHB Patients
  Beyond Treatment Indications by Current Guidelines\nEstimated primary com
 pletion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tenofovir-alafenamide-vemlidy#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03753074
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07553767-9804@assetmemo.bio
DTSTAMP:20261121T010001Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 1 readout est. (NCT07553767)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 1\, Chronic Hepatitis B
 .\nStudy: Efficacy and Safety of Pegylated Interferon Alpha-2β in Patient
 s With Hepatitis B-related Hepatocellular Carcinoma After Radical Resectio
 n\nEstimated primary completion: 31 December 2034. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07553767
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
